{"id":"mr-107a-02","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-15%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Vomiting"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SGLT2, MR-107A-02 reduces glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This mechanism is particularly beneficial for patients with type 2 diabetes.","oneSentence":"MR-107A-02 is a small molecule that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:22:13.165Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT06215859","phase":"PHASE3","title":"Study of MR-107A-02 for the Treatment of Acute Postoperative Pain Following Herniorrhaphy","status":"COMPLETED","sponsor":"Viatris Specialty LLC","startDate":"2023-12-29","conditions":"Acute Pain, Post Operative Pain, Pain","enrollment":579},{"nctId":"NCT06215820","phase":"PHASE3","title":"Study of MR-107A-02 for the Treatment of Acute Postoperative Pain Following Bunionectomy","status":"COMPLETED","sponsor":"Viatris Specialty LLC","startDate":"2023-12-29","conditions":"Acute Pain, Post Operative Pain, Pain","enrollment":410},{"nctId":"NCT05317312","phase":"PHASE2","title":"Study of MR-107A-02 in the Treatment of Post Surgical Dental Pain.","status":"COMPLETED","sponsor":"Mylan Specialty, LP","startDate":"2022-03-31","conditions":"Acute Pain, Post Operative Pain, Pain","enrollment":111}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"MR-107A-02","genericName":"MR-107A-02","companyName":"Viatris Specialty LLC","companyId":"viatris-specialty-llc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"MR-107A-02 is a treatment being studied for post surgical dental pain, acute pain, and pain. It is being compared to a placebo and tramadol in a randomized, double-blind, placebo-controlled study.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}